Premium
Treatment of respiratory syncytial virus infection in adult patients with hematologic malignancies based on an institution‐specific guideline
Author(s) -
McCoy D.,
Wong E.,
Kuyumjian A.G.,
Wynd M.A.,
Sebti R.,
Munk G.B.
Publication year - 2011
Publication title -
transplant infectious disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.69
H-Index - 67
eISSN - 1399-3062
pISSN - 1398-2273
DOI - 10.1111/j.1399-3062.2010.00561.x
Subject(s) - medicine , ribavirin , guideline , respiratory system , virus , palivizumab , hematopoietic stem cell transplantation , hematologic disorders , immunology , intensive care medicine , transplantation , pathology , hepatitis c virus
D. McCoy, E. Wong, A.G. Kuyumjian, M.A. Wynd, R. Sebti, G.B. Munk. Treatment of respiratory syncytial virus infection in adult patients with hematologic malignancies based on an institution‐specific guideline.
Transpl Infect Dis 2011: 13: 117–121. All rights reserved Abstract: A total of 26 adults with hematologic malignancies and/or hematopoietic stem cell transplant were treated for respiratory syncytial virus (RSV) infection based on an institutional guideline. Thirteen patients received aerosolized ribavirin, and 13 received aerosolized ribavirin and intravenous palivizumab. Two deaths, not attributed to RSV infection, occurred within 90 days of diagnosis.